To determine the predictive value of abnormalities on high-resolution CT (HRCT) on pulmonary disease in systemic sclerosis. Patients: Fifty-two patients suffering from systemic sclerosis. Design: Pulmonary disease was defined by pulmonary function test abnormalities, ie, total lung capacity (TLC) <80% of predicted value and/or diffusion of carbon monoxide (DLCO) <75% of predicted value, without any pulmonary event other than systemic sclerosis in the medical history. Patients were divided in two groups, group A with pulmonary disease (29 patients) and group B without pulmonary disease (23 patients). HRCT abnormalities were scored on whole lungs. A decision matrix was constructed to determine sensitivity, specificity, positive and negative predictive values, and false-positive and false-negative rates. A receiver operating characteristic curve was constructed to determine the best compromise between sensitivity and specificity. Results: HRCT total scores were higher in group A (9.0 ؎ 4.3) than in group B (5.0 ؎ 2.8) (p < 0.001) and they correlated with TLC (r ‫؍‬ ؊0.39, p < 0.005) and DLCO (r ‫؍‬ ؊0.50, p < 0.0002). An HRCT score of 7 corresponded to the best compromise between sensitivity (0.60) and specificity (0.83), with a positive predictive value of 0.82. Taking into account a value of 10 for the HRCT score increased specificity to 1 but decreased sensitivity to 0.41. Conclusion: A minimum score of 7 would be required to consider HRCT abnormalities in systemic sclerosis as predictive of pulmonary disease. An HRCT score of 10 makes it possible to establish the diagnosis of lung involvement severe enough to impair pulmonary function.
P
ulmonary involvement is frequent in systemic sclerosis. It is reported in 70% 1 to 100% 2 of patients in autopsy series. It leads to a decrease in lung volumes and gas transfer across the alveolocapillary barrier, and the alterations in pulmonary function provide the prognosis of the disease. Although open lung biopsy remains the gold standard to diagnose interstitial lung disease, high-resolution CT (HRCT) is considered to be the reference among the noninvasive procedures. It allows very precise analysis of lung parenchyma, with the advantage of assessing both lung volumes. 3 However, some patients present with HRCT abnormalities suggesting interstitial lung disease, although lung volumes and gas exchange are not altered. 4 The significance of HRCT abnormalities in these patients remains unknown, and it is not clear whether they are at particular risk and would benefit from more intensive follow-up. Interstitial signs on HRCT are not equal in significance and honeycombing, for example, has a worse prognosis than ground-glass appearance. 5 The extent of lesions also has to be considered. 3, 6 Warrick et al 7 have defined a score based on the criteria of type and extent of HRCT signs in systemic sclerosis patients. They found a negative correlation between single-breath carbon monoxide lung diffusion capacity (Dlco) and HRCT score.
The aim of the present study was to establish the HRCT score in 52 patients with systemic sclerosis and to quantify the predictive value of HRCT abnormalities on pulmonary disease, as assessed by pulmonary function tests (PFTs). Our hypothesis was that the HRCT might help to identify those patients at risk of pulmonary disease severe enough to alter pulmonary function, thus justifying more intensive follow-up or earlier treatment.
Materials and Methods

Study Population
Fifty-two patients with a diagnosis of systemic sclerosis (36 patients with limited scleroderma and 16 patients with diffuse scleroderma) referred consecutively to our institution for further evaluation were included in this study between September 1995 and March 1996. All patients gave their informed consent to participate in the study, which was approved by our local Ethics Committee. Systemic sclerosis was defined according to the American Rheumatism Association criteria. 8 There were 51 women and 1 man, aged 23 to 79 years (mean, 53 years). Time from diagnosis of systemic sclerosis to inclusion in the study ranged between 3 months and 37 years (mean, 5.6 years). Forty-seven patients were nonsmokers and five patients were ex-smokers. None of the patients had a recent history or signs of respiratory infection at the time of the study. Known histories of asthma, allergic alveolitis, or exposure to organic dusts were exclusion criteria. Treatment consisted of corticosteroids (1 patient), calcium channel blockers (50 patients), colchicine (16 patients), sulfasalazine (5 patients) and D-penicillamine (5 patients).
Pulmonary Function Tests
Forced inspiratory and expiratory flow volume curves and absolute lung volumes were measured in a constant-volume plethysmograph (Sensor Medics 28000; Yorba Linda, CA). A 10-s single-breath Dlco test (Morgan; Kent, UK) was carried out. The results were expressed as percentages of normal predicted values for age, height, and sex. 9, 10 Pulmonary function was considered abnormal if total lung capacity (TLC) was Ͻ80% and/or Dlco Ͻ75% of predicted values. 11, 12 
HRCT Scanning
All patients underwent an HRCT scan of the chest (CT Hispeed; GE, Milwaukee, WI) on the same day that they had PFTs. One-millimeter-thick slices (200 mAs, 120 kV) performed at the end of inspiration were obtained from apex to base with a table increment of 10 mm. The scanning time was 1 s for each slice. Adequate field of view according to the patient's morphology was used. No gantry angulation was required. Prone sections were performed when posterior images obtained on supine sections were suspected of having artifacts due to gravitydependent perfusion. Images were reconstructed with a 512 ϫ 512 matrix. We used a high-resolution algorithm selecting only high frequencies (Bone algorithm). All examinations were filmed with two window levels (300 to 30, 1,600 to 500 Hounsfield units) for review. HRCT scans were read by two independent radiologists in random order, without knowledge of the results of the other's findings. The parenchymal abnormalities identified on HRCT were coded and a score was defined according to Warrick et al. 7 A point value was assigned to each abnormality (ground-glass appearance, 1; irregular pleural margins, 2; septal/subpleural lines, 3; honeycombing, 4; subpleural cysts, 5). For each patient, a "severity of disease" score was obtained by adding these point values. An "extent of disease" score was obtained by counting the number of bronchopulmonary segments involved for each abnormality: 1 to 3 segments scored 1; 4 to 9 segments scored 2; Ͼ9 segments scored 3. Finally, severity of disease and extent of disease scores were added to form a total HRCT score, with a possible range of 0 to 30. For example, a patient with a ground-glass appearance (severity of disease score 1) in the three segments of the right lower lobe (extent of disease score 3) and honeycombing (severity of disease score 4) in two segments (extent of disease score 2) would have a total HRCT score of 8.
There was a strong correlation between the scores of the two radiologists (y ϭ 1.02x ϩ 0.65, r ϭ 0.98). Agreement, which was very good ( ϭ 0.869), was quantified by kappa test after grouping the HRCT scores in six classes (0 to 2, 3 to 5, 6 to 8, 9 to 11, 12 to 14, 15 and above). However, in 21 cases, there was minimal disagreement between the two radiologists (1 point in 15 cases, 2 points in 5 cases, 3 points in 1 case). In these cases, a consensus was obtained after a third common reading, and these final results were used for further analysis.
Analysis of Results
Pulmonary disease was defined by PFT abnormalities, ie, TLC Ͻ80% of predicted value and/or Dlco Ͻ75% of predicted value, without any pulmonary event other than systemic sclerosis in the medical history. Patients were divided into two groups, group A with pulmonary disease and group B without pulmonary disease. The two groups were compared in terms of age (ANOVA) and cutaneous extent of the disease ( 2 test). Mean value and SD of TLC and Dlco were determined in each group. HRCT scores were analyzed according to the two stages of cutaneous extent of scleroderma (limited scleroderma and diffuse scleroderma) using one-way ANOVA.
HRCT scores were compared between groups A and B (ANOVA) and were correlated with TLC, FVC, and Dlco in the whole study group using the least square method. A decision matrix was constructed to determine sensitivity, specificity, and positive and negative predictive values of HRCT score to predict alterations in pulmonary function tests. Receiver operating characteristic (ROC) curves were constructed from both radiologists' scores according to a previously described method. 13 These ROC curves were used to determine the best compromise between sensitivity and specificity.
Results
Twenty-nine patients (patients 1 to 29) were in group A (Table 1) , and 23 patients (patients 30 to 52) were in group B (Table 2 ). There was no significant difference between the two groups regarding age (group A, 55 Ϯ 14.8 years; group B, 52 Ϯ 13.3 years; mean Ϯ SD). There was a difference between the two groups in terms of cutaneous extent of the disease. In group A, 16 patients (55.2%) had limited scleroderma and 13 patients (44.8%) had diffuse scleroderma. In group B, 20 patients had limited scleroderma (87.0%) and 3 patients had diffuse scleroderma (13.0%). Patients with diffuse scleroderma had significantly higher HRCT scores (9.1 Ϯ 5.2, mean Ϯ SD) than patients with limited scleroderma (6.4 Ϯ 3.5, mean Ϯ SD) (p Ͻ 0.04).
Individual values for TLC and Dlco, expressed as percentage of predicted values, are presented in Tables 1 and 2 HRCT scores were significantly higher in group A than in group B (Fig 1) . They ranged from 0 to 18 (9.0 Ϯ 4.3, mean Ϯ SD) in group A and from 0 to 10 (5.0 Ϯ 2.8, mean Ϯ SD) in group B (p Ͻ 0.001). HRCT scores correlated with TLC (r ϭ Ϫ0.39, p Ͻ 0.005) (Fig 2) and with Dlco (r ϭ Ϫ0.50, p Ͻ 0.0002) (Fig 3) , but not with FVC.
HRCT scores are presented in Tables 1 and 2 . Table 3 presents the values of sensitivity, specificity, and positive and negative predictive values for scores from 0 to 18, the highest score observed in our series. The ROC curves obtained from both radiologists' scores are presented in Figure 4 . As shown on the figure, they are very similar and do not differ significantly in terms of the area under the curves (0.774 Ϯ 0.064 for the first radiologist and 0.754 Ϯ 0.067 for the second radiologist). In both cases, a total HRCT score of 7 corresponded to the best compromise between sensitivity and specificity to predict PFT abnormalities. Using this score, sensitivity was 0.60, specificity 0.83, positive predictive value 0.82, and negative predictive value 0.62. In group A, 11 patients (patients 2, 7, 8, 9, 12, 13, 20, 21, 22, 23, and 24) had a score equal to or less than 7. Of these patients, eight patients (patients 2, 7, 9, 12, 20, 21, 22, and 23) had only a decrease in Dlco without a decrease in TLC. Taking into account a value of 10 for the HRCT total score would increase the positive predictive value and specificity to 1 but would decrease the sensitivity to 0.40 (Table 3) . CHEST / 114 / 6 / DECEMBER, 1998
Discussion
In this study, we introduced a new element in the use of lung HRCT in systemic sclerosis that consists of using a previously defined score of 7 to assess the predictive value and specificity of abnormalities on HRCT to predict pulmonary scleroderma as defined by PFT abnormalities. There have been several stages in defining the role of HRCT to assess interstitial lung disease. The first, purely descriptive, stage was to define the semiology of interstitial lung disease on HRCT. Indeed, HRCT provides excellent parenchymal detail and it is now widely accepted as the reference technique for noninvasive diagnosis of interstitial lung disease. 14 -16 In systemic sclerosis patients with lung involvement, HRCT abnormalities correlate with lung histology. 3 Parenchymal opacification associated with a reticular pattern corresponds to inflammatory histology, whereas a reticular pattern alone is associated with fibrotic histology. 5 These findings suggested that HRCT analysis might be used to predict the prognosis of lung involvement. 5, 17 The second stage was to improve the potential of HRCT to quantify the lung abnormalities. For this purpose, Warrick et al 7 defined a scoring system taking into account the types of abnormality and their extent. However, the potential of this score in terms of its predictive value and specificity to predict the probability of pulmonary scleroderma has not yet been assessed. This is a question of clinical importance because it remains uncertain if patients with HRCT abnormalities but normal PFT results would require more intensive follow-up.
By quantifying abnormalities on lung HRCT in 52 systemic sclerosis patients using the Warrick et al 7 score and with reference to the PFT results of each patient, we were able to determine the sensitivity, specificity, and predictive value of each individual score between 0 and 18, the maximum score in our patients. HRCT scores were determined on the basis of readings of two independent radiologists that correlated. The maximum discrepancy was 3 points in one case whereas the maximum possible score was 30. A consensus was obtained in all cases after a common third reading. Active smoking or recent respiratory tract infec- CHEST / 114 / 6 / DECEMBER, 1998
tions, which might have interfered with the interpretation of HRCT, were exclusion criteria. The two groups of patients, ie, group A with alterations in PFT results (29 patients) and group B with normal PFT results (23 patients), were similar in terms of age but differed regarding the extent of cutaneous disease. The proportion of patients with the more extensive stage of cutaneous disease (diffuse scleroderma) was higher in group A. Correlation between visceral involvement and cutaneous extent of the disease has already been reported in systemic sclerosis. 17 This was confirmed in our study in which analysis of the whole series demonstrated that diffuse scleroderma is more frequently associated with PFTs and lung HRCT abnormalities than acroscleroderma. HRCT scores were significantly higher in group A than in group B (p Ͻ 0.001) and there was a strong inverse correlation between HRCT score and TLC (p Ͻ 0.005) and, in addition, between HRCT score and Dlco (p Ͻ 0.0002). Decrease in Dlco is considered to be a sensitive indicator of lung involvement, 17 which may precede reduction in lung volume. 18 In general, and especially in systemic sclerosis that can affect the vascular bed independently of the degree of interstitial fibrosis, 19 decrease in Dlco can reflect either epithelial and/or endothelial abnormalies. 20 The HRCT abnormalities that have been reported in systemic sclerosis patients with pulmonary involvement depict interstitial lesions and not endothelial lesions. 5, 16 Although to our knowledge this has not been evaluated per se, HRCT might therefore be more effective in detecting epithelial than in detecting endothelial abnormalities. This might, at least in part, explain the score Յ7 in 11 patients in group A. Indeed, 8 of the 11 patients in group A had an isolated decrease in Dlco without decrease in TLC. Lung parenchymal involvement constitutes a worsening factor in systemic sclerosis. To detect lung involvement as early as possible would make it possible to protect patients from tobacco and aerocontaminants. 21 According to ROC analysis, a score of 7 corresponded to the best compromise between sensitivity (0.60) and specificity (0.83), with a posi- Figure 4 . ROC for determination of the best HRCT score. Sensitivity and specificity were calculated for various HRCT scores. Best score (arrow) is the point at which the false-negative rate (100-specificity) increases more than the sensitivity rate, ie, 7. First radiologist ϭ white points, solid line and arrow. Second radiologist ϭ black points, dotted line and arrow. tive predictive value of 0.82. Although responses to immunosuppressive treatment might be better in the earlier stages, 22 there is no consensus today on the way patients should be treated if their conditions are diagnosed at the very early stage of lung involvement. 23 For this reason, and because the problem with HRCT in systemic sclerosis appears to be related to a lack of specificity rather to sensitivity, we assessed the impact of considering a higher score on a decision matrix. A score of 10 would increase the predictive value and specificity to 1 but it would decrease sensitivity to 0.40. Use of the Warrick et al 7 score has therefore to be considered, taking into account the concepts of sensitivity, specificity, and predictive value that may influence the clinical relevance of HRCT.
In conclusion, the Warrick et al 7 score allows not only quantification of lung lesions on HRCT but also prediction of the impact of these lesions on pulmonary function, according to the score. The use of our decision matrix, based on finding in 52 patients, should enhance the cost-effectiveness of HRCT and its impact on the care of systemic sclerosis patients suspected of having lung involvement.
